1. In Vivo

Dealmaking Quarterly Statistics, Q1 2024

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, January-March 2024

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device company M&A values reached $3.6bn, while in vitro diagnostics and research tools players’ M&A activity totaled $1bn.

Qstats Image 1
• Source: Alamy

Biopharma merger and acquisition value for the third quarter of 2023 reached $37bn from 39 transactions, 26 of which had disclosed values. Making up almost half (45%) of that total was life sciences investor Novo Holdings’ proposed $16.5bn buy of public contract manufacturing and development organization (CDMO) Catalent. Along with this deal, eight other transactions hit or exceeded the billion-dollar mark during Q1 (see Exhibit 1).

The Catalent buy-out was the largest M&A deal of the quarter. Founded in 2007 by affiliates of the Blackstone Group,...

More from Deal-Making

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.